Loading organizations...
Loading organizations...
Gene silencing platform for programmable allogeneic cell therapies.
Laverock Therapeutics has raised $43.5M across 2 funding rounds.
Laverock Therapeutics has raised $43.5M in total across 2 funding rounds.
Laverock Therapeutics has raised $43.5M in total across 2 funding rounds.
Laverock Therapeutics's investors include Elizabeth Klein, Eli Lilly and Company, Eos Advisory, Maven Capital Partners, Mercia Ventures, Norcliffe Capital, Calculus Capital, Tekfen Ventures, UK Innovation & Science Seed Fund.
Laverock Therapeutics has raised $43.5M across 2 funding rounds. Most recently, it raised $27.1M Seed Extension in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 30, 2025 | $27.1M Seed Extension | Elizabeth Klein | Eli Lilly and Company, Eos Advisory, Maven Capital Partners, Mercia Ventures, Norcliffe Capital |
| Sep 28, 2023 | $16.4M Seed | Calculus Capital | Eli Lilly and Company, Eos Advisory, Maven Capital Partners, Mercia Ventures, Tekfen Ventures, UK Innovation & Science Seed Fund |